{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:40:30Z","timestamp":1791873630319,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Proton therapy (PT) is an advanced form of radiation therapy that exploits the physical properties of the Bragg peak to deliver highly conformal dose distributions while minimizing radiation exposure to surrounding normal tissues. This precision is particularly relevant in prostate cancer, where critical organs at risk, including the rectum, bladder, bowel, and penile bulb, are in close proximity to the target. This review summarizes the evolution of PT techniques for prostate cancer, from early passively scattered proton therapy (PSPT) to contemporary intensity-modulated proton therapy (IMPT), and evaluates their dosimetric and clinical implications across multiple treatment settings. Dosimetric studies consistently demonstrate that PT, particularly IMPT, reduces integral dose and improves normal tissue sparing compared with photon-based modalities (XRT) such as intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), especially in low- to intermediate-dose regions. These advantages are most pronounced for complex target volumes, including pelvic nodal irradiation and focal intraprostatic boosting. Clinical outcomes data for prostate only treatment indicate excellent disease control with low rates of high grade gastrointestinal and genitourinary toxicity. Emerging evidence suggests potential benefits of PT in reducing specific rectal symptoms and lowering the risk of secondary malignancies. For high-risk prostate cancer requiring pelvic irradiation, prospective and registry-based studies demonstrate favorable toxicity profiles with IMPT, supporting its use in extended treatment fields. In the postoperative setting, PT offers dosimetric improvements, though clinical benefits over XRT remain less clearly defined. Additionally, these advancements in technology have allowed for more precise hypofractionated treatment, including proton stereotactic body radiation therapy, without significant increases in genitourinary or gastrointestinal toxicity. Finally, ultra-high dose rate FLASH PT may further enhance the therapeutic ratio. Overall, modern PT represents a highly precise and evolving modality in prostate cancer management, with the potential to optimize oncologic outcomes while preserving long-term quality of life. Further randomized and cost effectiveness studies are needed to fully define its role relative to advanced photon techniques.<\/jats:p>","DOI":"10.3389\/fonc.2026.1775107","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:14:29Z","timestamp":1776399269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Modern proton therapy in prostate cancer: precision in practice"],"prefix":"10.3389","volume":"16","author":[{"given":"Irini","family":"Yacoub","sequence":"first","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Biological Science, University of California San Diego","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyi","family":"Wei","sequence":"additional","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]},{"name":"Department of Radiation Oncology, Mount Sinai Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit M.","family":"Chhabra","sequence":"additional","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]},{"name":"Department of Radiation Oncology, Mount Sinai Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur J.","family":"Mehta","sequence":"additional","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]},{"name":"Department of Radiation Oncology, Montefiore Einstein Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Oska","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Montefiore Einstein Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Montefiore Einstein Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehee Isabelle","family":"Choi","sequence":"additional","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[{"name":"New York Proton Center","place":["New York, NY, United States"]},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.010.10529","article-title":"Proton therapy in clinical practice","volume":"30","author":"Liu","year":"2011","journal-title":"Chin J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx208","article-title":"Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review","volume":"110","author":"Verma","year":"2018","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00261","article-title":"Secondary Malignancy risk following proton radiation therapy","volume":"5","author":"Eaton","year":"2015","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.12.041","article-title":"Temporal evolution and diagnostic diversification of patients receiving proton therapy in the United States: a ten-year trend analysis (2012 to 2021) from the National Association for Proton Therapy","volume":"119","author":"Hartsell","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180004","article-title":"Proton relative biological effectiveness (RBE): a multiscale problem","volume":"92","author":"Underwood","year":"2018","journal-title":"Br J Radiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17233724","article-title":"RBE-guided treatment planning, LET optimization, and implications of proton arc therapy for the sparing of nervous tissue in head and neck proton therapy","volume":"17","author":"Reiners","year":"2025","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3791\/58372","article-title":"Proton therapy delivery and its clinical application in select solid tumor Malignancies","author":"Kaiser","year":"2019","journal-title":"J Vis Exp"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.03.018","article-title":"Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison","volume":"69","author":"Trofimov","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13014-015-0522-5","article-title":"Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer","volume":"10","author":"Yeo","year":"2015","journal-title":"Radiat Oncol Lond Engl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020403","article-title":"Dosimetric comparison study of proton therapy using line scanning versus passive scattering and volumetric modulated arc therapy for localized prostate cancer","volume":"16","author":"Takagi","year":"2024","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aa772e","article-title":"A beam monitoring and validation system for continuous line scanning in proton therapy","volume":"62","author":"Klimpki","year":"2017","journal-title":"Phys Med Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1241711","article-title":"Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study","volume":"13","author":"Ong","year":"2023","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.14338\/IJPT-18-00048.1","article-title":"IMPT versus VMAT for pelvic nodal irradiation in prostate cancer: a dosimetric comparison","volume":"5","author":"Whitaker","year":"2019","journal-title":"Int J Part Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.02.038","article-title":"Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer","volume":"95","author":"Bryant","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): phase III randomized clinical trial of proton therapy vs. IMRT for localized prostate cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28536","article-title":"Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer","volume":"120","author":"Hoppe","year":"2014","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110264","article-title":"Photon vs proton hypofractionation in prostate cancer: a systematic review and meta-analysis","volume":"195","author":"Corrao","year":"2024","journal-title":"Radiother Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14338\/IJPT-23-00002.1","article-title":"Case-matched outcomes of proton beam and intensity-modulated radiation therapy for localized prostate cancer","volume":"10","author":"Bao","year":"2023","journal-title":"Int J Part Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.14338\/IJPT-20-00094.1","article-title":"Proton therapy of prostate and pelvic lymph nodes for high risk prostate cancer: acute toxicity","volume":"8","author":"Choo","year":"2021","journal-title":"Int J Part Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijrobp.2024.11.115","article-title":"Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer","volume":"122","author":"Choo","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24525","article-title":"Proton therapy for high-risk prostate cancer: results from the Proton Collaborative Group PCG 001\u201309 prospective registry trial","volume":"83","author":"Hasan","year":"2023","journal-title":"Prostate"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S806","DOI":"10.1016\/j.ijrobp.2010.07.1866","article-title":"Dosimetric comparison of VMAT, IMRT and proton therapy for post-prostatectomy radiation therapy for prostate cancer","volume":"78","author":"Doyle","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.14338\/IJPT-20-00021.1","article-title":"Postoperative or salvage proton radiotherapy for prostate cancer after radical prostatectomy","volume":"7","author":"Kharod","year":"2021","journal-title":"Int J Part Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32457","article-title":"Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting","volume":"125","author":"Santos","year":"2019","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2016.01.002","article-title":"Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: analysis of quality of life and toxicity, PCG GU 002","volume":"21","author":"Vargas","year":"2016","journal-title":"Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000241","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002","volume":"41","author":"Vargas","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpt.2024.100020","article-title":"The status and challenges for prostate stereotactic body radiation therapy treatments in United States proton therapy centers: an NRG Oncology practice survey","volume":"11","author":"Shen","year":"2024","journal-title":"Int J Part Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5843","article-title":"Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 nonrandomized trial","volume":"9","author":"Mascia","year":"2023","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040798","article-title":"Pencil beam scanning proton Bragg peak conformal FLASH in prostate cancer stereotactic body radiotherapy","volume":"16","author":"Kaulfers","year":"2024","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.013","article-title":"Linear energy transfer-guided optimization in intensity modulated proton therapy: feasibility study and clinical potential","volume":"87","author":"Giantsoudi","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"015013","DOI":"10.1088\/1361-6560\/aa9a2e","article-title":"Linear energy transfer incorporated intensity modulated proton therapy optimization","volume":"63","author":"Cao","year":"2017","journal-title":"Phys Med Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.024","article-title":"Exploratory investigation of dose-linear energy transfer (LET) volume histogram (DLVH) for adverse events study in intensity modulated proton therapy (IMPT)","volume":"110","author":"Yang","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.11.068","article-title":"Robust optimization for spot-scanning proton therapy based on dose-linear-energy-transfer volume constraints","volume":"121","author":"Chen","year":"2025","journal-title":"Int J Radiat Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.624786","article-title":"The emerging potential of multi-ion radiotherapy","volume":"11","author":"Ebner","year":"2021","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/mp.70077","article-title":"Multi\u2010modality biological dose optimization for combined carbon\u2010ion and proton radiation therapy","volume":"52","author":"Wang","year":"2025","journal-title":"Med Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:14:32Z","timestamp":1776399272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1775107"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1775107","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1775107"}}